Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mutations in Non-muscle Genes”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Not applicableStudy completedNCT00083499
What this trial is testing

Mutations in Genes Associated With Pentalogy of Cantrell

Who this might be right for
Pentalogy of Cantrell
National Heart, Lung, and Blood Institute (NHLBI) 59
Testing effectiveness (Phase 2)Active Not RecruitingNCT04917809
What this trial is testing

Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Who this might be right for
Bladder CancerRecurrent Bladder CancerFGFR3 Gene Mutation
Memorial Sloan Kettering Cancer Center 20
Not applicableWithdrawnNCT00477932
What this trial is testing

Genes Mutation Pentalogy of Cantrell

Who this might be right for
Pentalogy of CantrellMutations in Non-muscle Genes
Children's Healthcare of Atlanta
Testing effectiveness (Phase 2)Study completedNCT03213665
What this trial is testing

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin Lymphoma+38 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Looking for participantsNCT06995677
What this trial is testing

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT05544552
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Who this might be right for
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaSolid Tumor+11 more
Tyra Biosciences, Inc 310